Akari Therapeutics Plc — Form 10-Q
Filed August 13, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 5/100
What the filing says
The filing is a standard Form 10-Q for the quarter ended June 30, 2026, filed August 13, 2026. The document header and filing metadata are provided, but the actual financial statements, management discussion, and operational details are not present in the text supplied. No specific counterparties, dollar amounts, share counts, or material business developments can be identified from this excerpt.
Why this rating
Routine quarterly filing submission; no substantive financial or operational data disclosed in provided text. Unable to assess material changes.
See more from August 13, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.